Live Breaking News & Updates on Tech Biologics

Stay updated with breaking news from Tech biologics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

LimmaTech Biologics Reports Positive Interim Phase I/II Clinical Data on Tetravalent Shigella Bioconjugate Vaccine S4V

SCHLIEREN, Switzerland, February 22, 2024 LimmaTech Biologics AG announced positive interim data from its Phase I/II clinical trial evaluating Shigella4V (S4V), a tetravalent bioconjugate vaccine candidate against shigellosis, an infectious disease caused by Shigella bacteria. Shigellosis is a serious infection and remains the second leading cause of fatal diarrheal disease, particularly in infants in low- and middle-income countries. In the nine-month-old target population, administration of S ....

United Kingdom , Limmatech Biologics , Alexander Siebert , Patricia Martin , Franz Werner Haas , Network Meeting , Trophic Communications , Chief Operating Officer , Annual Network Meeting , Wellcome Trust , Gram Negative Shigella , Tech Biologics , Werner Haas , Clinical Trial , Vaccine Candidate , Diarrheal Disease , Tolerability Profile , Topline Results , Target Population , Clinical Development ,

LimmaTech Biologics Adds Additional $3 Million in Series A Second Closing Bringing Total Raised to $40 Million

LimmaTech Biologics Adds Additional $3 Million in Series A Second Closing Bringing Total Raised to $40 Million
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Franz Werner Haas , Paul Wolfrom , Alexander Siebert , Nicola Forrest , Limmatech Biologics , Steve Burnell , Stefan Klotter , Trophic Communications , Impact Fund , Novo Holdings , Adjuvant Capital , Chief Executive Officer , Managing Director , Chief Financial Officer , Tech Biologics , Werner Haas , Die Performance Strategie , Assets Sie ,